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Absence of Intragraft B Cells in Rejection Biopsies
After Rituximab Induction Therapy:
Consequences for Clinical Outcome
Martijn W.F. van den Hoogen, MD, PhD,1 Eric J. Steenbergen, MD, PhD,2 Marije C. Baas, MD, PhD,3
Sandrine Florquin, MD, PhD,2,4 and Luuk B. Hilbrands, MD, PhD3
Background. The pathophysiological role of intragraft B cells during renal allograft rejection is unclear.Methods.We studied
B-cell infiltration during acute rejection in 53 patients who participated in a clinical trial in which adult renal transplant patients were
randomized between a single intraoperative dose of rituximab (375 mg/m2) or placebo as induction therapy. Two indepen-
dent pathologists scored all biopsies in a blinded fashion according to the Banff classification and scored for the presence
of B cells and plasma cells using CD79a and CD138 as markers. Results. The majority of acute rejections were T cell–mediated.
The proportion of acute rejections with an antibody-mediated component tended to be lower in rituximab-treated patients
(4/23, 17.4%) than in placebo-treated patients (11/30, 36.7%; P = 0.14). Biopsies of rituximab-treated patients had signifi-
cantly lower scores for B cells (0.00; range, 0.00-0.50 vs 1.70; range, 0.60-3.30; P < 0.0001) and plasma cells (0.10; range,
0.00-1.90 vs 0.40; range, 0.00-7.50; P = 0.006). During acute rejection, intragraft clusters of B cells were not observed after
rituximab induction therapy. However, the depletion of intragraft B cells during acute rejection did not affect steroid resis-
tance, proteinuria, graft function at 2 years follow-up, or patient and graft survival at a median follow-up of 4.1 years (range,
2.0-6.2 years). Conclusions. These data do not support a harmful influence of intragraft B cells present during acute allograft
rejection on the clinical course within the first few years after renal transplantation.
(Transplantation Direct 2017;3: e143; doi: 10.1097/TXD.0000000000000659. Published online 10 March, 2017.)
During acute allograft rejection, different cell types caninfiltrate the graft, such as T cells, NK cells, monocytes,
and also B cells. The clinical relevance of infiltrating B cells is
a matter of debate. Some studies show an association with a
poorer response to antirejection therapy and hence worse
graft outcome, whereas other studies do not show a negative
impact of B cell infiltration on graft outcome.1-4
Rituximab is a monoclonal antibody against the CD20
antigen present on different types of B cells. After adminis-
tration of a single dose, it rapidly induces complete and
long-lasting B cell depletion in the peripheral blood.5
However, in secondary lymphoid organs, like lymph nodes
and spleen, B cell depletion after a single dose of rituximab
is incomplete.6,7Many case series have suggested a beneficial
effect of rituximab in the treatment of (antibody-mediated)
renal allograft rejection, but these results are difficult to inter-
pret without a control group. In a small randomized trial
(n = 20), treatment with rituximab (next to antithymocyte
globulin and/or high-dose steroids) resulted in a larger im-
provement of graft function and of biopsy rejection scores
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at six months post-treatment, compared to treatment with
antithymocyte globulin and/or high dose steroids alone.8
This improvement was accompanied by complete intragraft
B-cell depletion in all rituximab-treated patients at follow-up.
Although rituximab had no apparent effect on donor specific
antibody levels, reappearance of C4d deposition was not
seen on follow-up biopsies after rituximab treatment. These
findings suggest a pathogenic role of intragraft B cells in acute
renal allograft rejection.
In addition to its use for the treatment of rejection, rituxi-
mab has been studied for prevention of acute rejection. We
have performed a double-blind, placebo-controlled study, in
which 280 adult renal transplant patients were randomized
between a single dose of rituximab (375 mg/m2) or placebo
during transplant surgery.9 Patients were stratified according
to panel-reactive antibody value and rank number of trans-
plantation. Maintenance immunosuppression consisted of
tacrolimus, mycophenolate mofetil, and steroids. This study
showed that a single dose of rituximab as induction therapy
did not reduce the overall incidence of biopsy proven acute
rejection, but might be beneficial in patients with higher im-
munological risk. Other studies have shown similar results
in immunologically low-risk patients, although one small
study reported an increased risk of rejection with rituximab
therapy.10,11
Here we compare graft histology during acute rejection in
patients with and without rituximab as induction therapy,
with emphasis on the effect of rituximab induction therapy
on type of rejection (T cell–mediated versus antibody-
mediated) and intragraft B cell numbers. The main research
questions were whether rituximab induction treatment leads
to depletion of intragraft B cells during acute rejection and
whether this depletion is associatedwith a favorable outcome
(less steroid-resistance and improved graft function after
follow-up).
MATERIALS AND METHODS
The full details of the original clinical trial have been
described elsewhere.9 This trial was approved by the Com-
mittee onHuman-Related Research Arnhem-Nijmegen, con-
ducted according to the Declaration of Helsinki and good
clinical practice guidelines. In brief, 280 patients who
underwent a renal transplantation in the Radboud university
medical center, Nijmegen, The Netherlands, were random-
ized to treatment with a single intra-operative dose of
375mg/m2 body surface area rituximab (n = 138) or placebo
(n = 142) added to standard immunosuppression consisting
of tacrolimus, mycophenolate mofetil, and steroids. In this
trial, biopsies were only performed on clinical indication.
First line treatment of acute rejections consisted of methyl-
prednisolone, followed by anti–T cell antibodies (rabbit
antithymocyte globulin [Thymoglobulin], Genzyme;
Muromonab-CD3 [OKT3], Janssen-Cilag; alemtuzumab
[Campath], Genzyme) in case of steroid-resistance, defined
as lack of improvement of graft function within five days
after the first methylprednisolone dose.
We selected all patients who had a biopsy proven acute re-
jection within 6 months posttransplantation. We excluded bi-
opsies in which no rejection was diagnosed, because a cellular
infiltrate was generally absent in these cases. To rule out an
effect of earlier antirejection treatment on graft histology, we
only analyzed the first rejection biopsy in each patient.
The biopsy material was bouin-fixated and four-
micrometer sections were processed for routine histologic
stains including hematoxylin-eosin, Jones’ silver stain,
Masson Trichrome, and periodic acidic Schiff after diastase
treatment. Staining for C4d was performed on frozen
sections using immunofluorescence technique, with a mouse
polyclonal antihuman C4d antibody (Biogenesis Inc., Ede,
The Netherlands). Four-micrometer sections were incubated
with monoclonal antibodies directed at the B cell marker
CD79a (M7050, clone JCB117 by Dako, Glostrup, Denmark)
and the plasma cell marker CD138 (ILM3825-c1-clone
B-A38 by Immunologic, Klinipath, Duiven, The Netherlands).
As secondary antibody we used powervision Poly-HRP-
antimouse/rabbit/rat IgG (Immunologic, Klinipath, Duiven,
TheNetherlands).Detectionwas carried outwith the use of per-
oxidase as label and diaminobenzidine as substrate. We did not
stain for CD20, because that staining could be falsely negative
due to blockage of CD20 by rituximab. Moreover, we also
did not use CD19 as a B cell marker, because a monoclonal
antibody against CD19 for use in bouin-fixated tissue is not
available. Because CD79a is expressed on B cells as well as
plasma cells we performed a simultaneous staining for
CD138 to differentiate between B cells and plasma cells.
Two independent pathologists scored all biopsies in a
blinded fashion. Rejection was scored according to the
Banff 07 criteria for T cell–mediated rejection (TCMR) and
antibody-mediated rejection (AMR).12 According to the
Banff 07 classification, diffuse C4d staining (ie, >50% of
peritubular capillaries) was defined as positive. To differenti-
ate between clusters and scatteredpositive cells, CD79a+ cells
were scored in a manner as previously described (for CD20+
and CD3+ cells) and CD138+ cells were scored as the num-
ber of positive cells per high power field.4 Per biopsy speci-
men the whole cortical area was examined. A cluster of
B cells was defined as more than 30 CD79a + cells without
the interposition of tubules. For each high-power field,
the scattered CD79a + cells were scored according to an ordi-
nal scale ranging from 0 to 5, as defined in Table 1. For
each biopsy specimen, the total scores for CD79a + cells,
and the total numbers of CD79a + clusters were divided
by the number of high-power fields that were examined.
Statistical testing was performed according to distribution
and type of data (unpaired t test, Mann-Whitney U test, χ2
test, or Fisher exact test). Allograft loss and death were ana-
lyzed with the Kaplan-Meier method, and differences were
assessed by the log-rank test. Correlations between histological
TABLE 1.
Histological scoring of interstitial CD79a + cells
Histological scoring
No. positive cells
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scorings of CD79a and CD138 with clinical outcome were
assessed with Spearman ρ correlation coefficient. Analyses
were performed with IBM SPSS Advanced Statistics 21.0
and GraphPad Prism 5.03.
RESULTS
The clinical parent study was performed in 280 renal
transplant patients (138 rituximab-treated vs. 142 placebo-
treated). Overall, the groups were well balanced with respect
to recipient and donor characteristics.9 The number of
patients who underwent at least 1 renal biopsy was 46
(33%) in the rituximab group and 60 (42%) in the placebo
group (P = 0.12 byχ2 test). An acute rejectionwas diagnosed
in half of these patients (53/106), 23 rituximab-treated and
30 placebo-treated (Figure 1). The rituximab and
placebo-treated patients with acute rejection were balanced
with respect to demographic and clinical characteristics
(Table 2). The median time from transplantation to rejection-
biopsy was approximately 14 days (range, 2-180 days).
The results of the histological examination are shown in
Table 3 and Figure 2. With respect to the type of rejection,
AMR and AMR combined with TCMR were less frequent
in rejection-biopsies from patients treated with rituximab,
but this was not statistically significant (17.4% vs 36.7%,
p = 0.14 by Fisher exact test). No differences between
groups were observed in other rejection-related items
of the Banff scheme such as tubulitis, (t score), arteritis
(v score), inflammation (i score), and glomerulitis (g score)
(Figure 2).
The score for interstitial CD79a + cells was significantly
lower in rituximab-treated patients (median, 0.00; range,
0.00-0.50), compared with placebo-treated patients (median,
1.70; range, 0.60-3.30; P < 0.0001 byMann-WhitneyU test,
Figure 3). Clusters of CD79a + cells were found in the biop-
sies of four placebo-treated patients while these were never
present in biopsies of rituximab-treated patients. Interest-
ingly, in placebo-treated patients the score for interstitial
CD79a + cells was significantly lower in patients with
FIGURE 1. Trial profile of all patients.
TABLE 2.






Age, y 47.3 ± 13.5 51.2 ± 11.4
Male sex (%) 56.5 53.3
White race (%)b 95.7 96.7
Cause of end-stage renal disease (no. patients)
Glomerulonephritis 5 14
Diabetes mellitus 1 3
Urological disorder 5 4
Hypertension/vascular damage 2 0
Polycystic kidney disease 7 4
Uncertain or other 3 5
Type of donor (%)
Living 56.5 53.3
Deceased donation after circulatory death 4.3 20.0
Deceased donation after brain death 39.1 26.7
Donor age (yr) 55.1 ± 8.6 52.3 ± 11.0
HLA mismatches—A, B, and DR (n) 3.26 ± 1.10 3.20 ± 1.30
Panel-reactive antibody titer—highest assessment 2 (0-83) 2 (0-71)
Patients with retransplant (%) 8.7 20.0
Cold-ischemia time—deceased donors only, h 17.0 ± 4.8 16.1 ± 4.1
Days between transplantation and rejection biopsy, d 14 (3-180) 13 (2-161)
Calculated GFR at time of rejection, mL/minc 19 (0-40) 17 (0-48)
a Values are presented as mean ± standard deviation or median (range). Overall group differences were not significant.
b Race was determined by the investigator.
c For the calculated GFR on the basis of abbreviated Modification of Diet in Renal Disease criteria, the following formula was used: estimated GFR (mL/min per 1.73 m2) = 175 (serum creatinine/88.4)-1.154
(age)-0.203  (0.742 if female)  (1.212 if African American). In case of continued dialysis treatment, a GFR of 0 mL/min was used.13
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AMR (median, 1.00; range, 0.60-2.00) than in patients with-
out AMR (median, 2.00; range, 1.00-3.30; P = 0.002 by
Mann-Whitney U test).
The score for interstitial CD138 cells was also significantly
lower in rituximab-treated patients (median, 0.10; range,
0.00-1.90) compared with placebo-treated patients (median,
0.4; range, 0.00-7.50; P = 0.006 by Mann-Whitney U test,
Figure 3), although considerable overlap between the groups
existed. Clusters of CD138+ cells were found in the biopsies
of 2 placebo-treated patients, and not in biopsies of rituximab-
treated patients. None of the biopsies showed evidence of
the formation of ectopic lymphoid tissue (as in tertiary
lymphoid organs).
Although induction with a single intraoperative dose of
rituximab led to an almost complete absence of intragraft
CD79a + cells at the time of rejection, this did not translate
into a beneficial effect on the subsequent clinical outcome.
The percentage of steroid-resistant rejections did not differ
between rituximab and placebo-treated patients (43.5% vs
50.0%, P = 0.66 by Fisher exact test). Furthermore, there
was no difference in proteinuria or graft function at 2 years
posttransplant. Patient and graft survival at the end of
follow-up were comparable in both groups (Table 4; and
Figure S2, SDC, http://links.lww.com/PRSGO/A393). In
the placebo-treated patients, the biopsy score for interstitial
CD79a + and CD138+ cells were not correlated with either
TABLE 3.
Incidence and type of biopsy proven acute rejection at
6 monthsa
Variable Rituximab (n = 23) Placebo (n = 30)
TCMR (no.)
Type IA 5 6
Type IB 2 2
Type IIA 10 9
Type IIB 2 2
AMR, n 1 2
Combined rejections (no.)
AMR + Type IIA 2 9
AMR + Type IIB 1 0
C4d positive,
n (%)
4 (17.4) 11 (36.7)
a Biopsies were independently scored by 2 pathologists according to the Banff 07 classification.12 A
diagnosis of AMR required positive immunostaining for C4d, combined with either signs of microvas-
cular inflammation (g > 0 and/or ptc > 0) or intimal arteritis (v > 0).
FIGURE 2. Histological scores of biopsies during acute allograft rejection.
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improvement of estimated glomerular filtration rate (eGFR)
(from moment of rejection to 24 months posttransplant) or
absolute eGFR at 24 months posttransplant (Figures S1a
and S1b, SDC, http://links.lww.com/PRSGO/A393). Of the
four placebo-treated patients with CD79a + cell clusters in
their biopsies, 3 had functioning grafts at the end of follow-up,
while one patient died after 3 years with a functioning graft.
In 23 patients (12 in rituximab group; 11 in placebo
group), antirejection therapy with methylprednisolone pre-
ceded the biopsy by at least 1 day. Because this could have in-
fluenced graft histology, we performed an additional analysis
after exclusion of these 23 patients. In the remaining cohort
of 30 patients (11 rituximab-treated and 19 placebo-treated
patients) comparable results were found with respect to
CD79a score (median score, 0.05; range, 0.00-0.50 vs 2.00;
range, 0.70-3.30; P < 0.001) and again no correlation be-
tween B-cell depletion and clinical outcome was observed.
DISCUSSION
Infiltration of B cells is a frequent finding in biopsies of
patients with acute renal allograft rejection. Our data show
that in renal transplant patients who received a single intra-
operative dose of rituximab as induction therapy, intragraft
B cells were nearly absent during subsequent episodes of
acute allograft rejection. Moreover, the relative frequency
of pure AMRor combinedAMRand TCMRwas lower than
in placebo-treated patients. No differences were seen in the
severity of tubulitis, arteritis, or the extent of the cellular infil-
trate. Notably, the absence of intragraft B cells during acute
rejection did not appear to affect the subsequent clinical
course.
Like others, we previously showed that a single dose of ri-
tuximab at the time of renal transplant surgery results in a
rapid and long lasting depletion of B cells in the peripheral
blood.5,14 Even at 2 years after transplantation, the absolute
number of B cells in peripheral blood was still quite low as
compared with patients not treated with rituximab.14 We
also showed that despite complete depletion of B cells in the
peripheral blood the number of B cells in secondary lym-
phoid organs remained unaffected.6 Others have confirmed
that in the near absence of B cells in peripheral blood there
is a varying degree of reduction, but no complete depletion,
of B cells in spleen, lymph nodes, and synovial tissue after
treatment with rituximab.5,15-17 Together with our current
findings, these data suggest that rituximab either inhibits
the egress of B cells from secondary lymphoid organs or selec-
tively depletes B cells in peripheral blood. In both cases, there
is reduced migration of B cells to peripheral tissues such as
the renal allograft.
Earlier studies by Hippen et al1 and Sarwal et al,18 demon-
strated that the presence of CD20+ B cell infiltrates in the
graft at time of rejection is a bad prognostic sign. It was sug-
gested that the antigen presenting function of infiltrating
B cells might contribute to an augmented alloreactive response.
Based on these findings, it could be expected that the absence
of intragraft B cells in rituximab-treated patients had resulted
in a lower rate of steroid-resistance and better graft survival.
However, our data do not indicate that absence of intragraft
B cells during acute rejection, as observed in rituximab-treated
patients, translates into better outcome. The interpretation of
this finding could be biased by a stronger severity of rejections
occurring after B cell depletion by rituximab. This was un-
likely however, because Banff scores for tubulitis, arteritis,
inflammation, and glomerulitis were similar in biopsies of
rituximab-treated and placebo-treated patients. Moreover,
in the placebo-treated patients there was no correlation be-
tween the scattered or clustered presence of B cells and the
clinical course. In four placebo-treated patients B cell clusters
were found in the rejection biopsy, and after a median
follow-up of 4 years 3 of the four patients still had a good
and stable graft function. Notably, other authors were also
unable to demonstrate that intragraft B cells were associated
FIGURE 3. CD79a + and CD138+ scores in renal biopsies during
acute allograft rejection.
TABLE 4.






Patients with steroid-resistant rejection, n (%) 10 (43.5) 15 (50.0)
Calculated GFR at 2 y in patients with a functioning graft, mL/minb 33 (20-49) 38 (19-64)
Improvement of GFR from time of rejection till 2 y posttransplant
in patients with a functioning graft at 2 y, mL/min
11 (−3 to 35) 18 (−5 to 55)
Proteinuria at 2 y, g/10 mmol creatinine 0.20 (0.1-0.8) 0.10 (0.1-4.0)
Allograft survival at end of follow-up (%)c
Censored for death of patients with functioning graft 78.3 83.3
Uncensored for death of patients with functioning graft 60.9 70.0
Patient survival at end of follow-up (%)c 78.3 83.3
a Values are presented as mean ± standard deviation or median (range).
b For the calculated GFR on the basis of abbreviated Modification of Diet in Renal Disease criteria, the following formula was used: estimated GFR (mL/min per 1.73 m2) = 175 (serum creatinine/88.4)-1.154
(Age)-0.203  (0.742 if female)  (1.212 if African American).13
c median duration of follow-up, 4.1 years; range, 2.0-6.2 years.
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with a poorer response to high dose steroids or worse graft
survival.3,4,19-21
As for the B cells, the number of intragraft CD138+
plasma cells was lower in rituximab-treated patients than in
placebo-treated patients. Although the clinical significance
of this finding is uncertain, it suggests that intragraft B cells
can develop into plasma cells.
In the clinical trial overarching this study, a trend towards less
AMR was seen in rituximab-treated patients, compared to
placebo-treated patients (4/138, 2.9% vs. 11/142, 7.7%
P=0.11byFisher’s exact test). Remarkably, placebo-treatedpa-
tients with AMR had lower scores for interstitial CD79a + cells
than placebo-treated patients without AMR. Taken together,
this suggests that any B cells and plasma cells that are involved
in the process of AMR are residing outside the graft.
The interpretation of our data is somewhat limited by the
moderate number of patients, and relatively short follow-up
period. However, most rejections occurred within the
first 3 months after transplantation and all patients had
a follow-up of at least 2 years.
To conclude, induction therapy with rituximab strongly
reduced the number of infiltrating B cells at the time of acute
renal allograft rejection. This did not have an effect on the se-
verity of tubulitis, arteritis or the extent of the cellular infil-
trate, nor did it improve clinical outcome after treatment of
the rejection. These data do not support previous findings
suggesting that intragraft B cells that are present during acute
allograft rejection are harmful for the graft during a median
follow-up of 4 years.
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